Ascentage Pharma Group International (AAPG) Non-Current Deffered Revenue (2023 - 2025)

Ascentage Pharma Group International (AAPG) has reported Non-Current Deffered Revenue for 3 consecutive years, with $916451.9 the latest figure, recorded in Q4 2025.

• Quarterly Non-Current Deffered Revenue fell 97.35% year-over-year to $916451.9 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $916451.9 (down 97.35% YoY) and the FY2025 annual result came in at $929000.0, down 97.27% from the prior year.
• Non-Current Deffered Revenue eased to $916451.9 in Q4 2025 per AAPG's latest filing, from $34.6 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for AAPG reached as high as $34.6 million in Q4 2024 and fell as low as $916451.9 in Q4 2025.
• A 3-year average of $13.5 million and a median of $5.0 million in 2023 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2024 — Non-Current Deffered Revenue jumped 584.95% — and 2025, when it sank 97.35%.
• Year by year, Non-Current Deffered Revenue stood at $5.0 million in 2023, then soared by 584.95% to $34.6 million in 2024, then sank by 97.35% to $916451.9 in 2025.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $916451.9, $34.6 million, and $5.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.